Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.98 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.98 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.49 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resminostat SCHEMBL295541 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL1887878 | 0.99 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL1887874 | 0.99 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299843 | 0.98 | HDAC1 (0.96) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299845 | 0.98 | HDAC1 (0.96) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299686 | 0.97 | HDAC1 (0.94) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299688 | 0.97 | HDAC1 (0.94) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL3149324 | 0.97 | HDAC1 (0.94) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| SCHEMBL3149313 | 0.97 | HDAC1 (0.94) | HDAC1HDAC6HDAC3HDAC8HDAC2 | |
| Resminostat SCHEMBL299597 | 0.96 | HDAC1 (0.92) | HDAC1HDAC6HDAC3HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1778 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2025235998-A1 | PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNE MODULATORY ACTIVITY | IMMORTA BIO, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| CN-101287706-A | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors | NYCOMED GMBH (DE) | 2008-10-15 | — | — | CN | claimed |
| CN-101268070-A | Novel sulphonylpyrroles as inhibitors of HDAC novel sulphonylpyrroles | NYCOMED GMBH (DE) | 2008-09-17 | — | — | CN | claimed |
| EP-1928872-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | Nycomed GmbH (DE) | 2008-06-11 | — | — | EP | claimed |
| EP-1928826-A1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | Nycomed GmbH (DE) | 2008-06-11 | — | — | EP | claimed |
| US-20070184979-A1 | Novel sulfonylpyrroles | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| WO-2007039404-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | claimed |
| WO-2007039403-A1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | claimed |
| CN-1926103-A | Sulfonyl pyrroles as HDAC inhibitors | ALTANA PHARMA AG (DE) | 2007-03-07 | — | — | CN | claimed |
| EP-1725528-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | HDAC1 517/4885HDAC6 1590/4885HDAC3 1207/4885 |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | HDAC1 2078/4885HDAC6 102/4885HDAC3 1362/4885 |
| US-20070184979-A1 | Novel sulfonylpyrroles | HDAC1, HDAC4, HDAC3 | HDAC1 1/4885HDAC6 8/4885HDAC3 3/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | HDAC1 2312/4885HDAC6 814/4885HDAC3 3198/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | HDAC1 3880/4885HDAC6 4490/4885HDAC3 2618/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | HDAC1 71/4885HDAC6 665/4885HDAC3 97/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | HDAC1 1894/4885HDAC6 920/4885HDAC3 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.